Replies to post #244490 on Biotech Values

[WorstLuck]

I’m personally disappointed in how lackluster or outright bad RVNC’s share price has performed AFTER they got FDA approval. It’s not what I expected.

Sell the launch is the norm for a smaller bio on it's first approval. It's easy to find examples. This launch is already short of expectation. On the plus side, maybe they have reset the bar low enough to actually outperform (resetting of expectations.) Remains to be seen.

[rwwine]

In some ways, RVNC reminds me of MNTA in how some of us investors were dismayed with how things played out including but not limited to Executive leadership of the companies. We know how MNTA played out eventually when J&J spent $6.5 Billion. Will be interesting to see how RVNC plays out. Stay tuned.

[vinmantoo]

I’m personally disappointed in how lackluster or outright bad RVNC’s share price has performed AFTER they got FDA approval. It’s not what I expected.

They had a fair amount of time to manufacture their product. If they knew they would need to train people in how to administer it, I am surprised they didn’t address the issue sooner.

I was surprised at the length of time they anticipate to ramp up sales.

I feel somewhat similarly. However, in the end the slow ramp up of sales doesn't matter. Well, it does if you use the time to buy a bit more RVNC at lower prices before sales ramp up.

[DewDiligence]

RVNC—I was surprised at the length of time they anticipate to ramp up sales.

Why are you (and other posters on this board) surprised? The Daxxify launch is proceeding in the manner RVNC has always said it would (#msg-165738386).